ME Therapeutics Holdings Inc. is a preclinical-stage biotechnology company specializing in the discovery and development of innovative immuno-oncology therapeutics, with a focus on combating immune suppression in cancer. The company’s core mission is to develop therapies that target suppressive myeloid cells within the tumor microenvironment—cells known to hinder the body’s immune response to cancer. Its lead candidate, h1B11-12, is a high-affinity glycoprotein cytokine antibody drug aimed at treating colorectal cancer by inhibiting mechanisms that facilitate immune evasion. Additional pipeline programs include small molecule myeloid-targeted prodrugs such as D094 and D099, as well as myeloid-targeting lipid nanoparticles, expanding its technological repertoire in precision oncology. The company has also initiated research into mRNA-based cancer therapeutics, signaling engagement with cutting-edge modalities in cancer treatment. Founded in 2014 and headquartered in Vancouver, ME Therapeutics Holdings Inc. plays a significant role in the biotechnology sector, striving to enhance anti-tumor immunity and address unmet needs in cancer therapy through novel, targeted approaches.